Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LENZ Therapeutics

交易中 07-07 13:50:45 EDT

5.97

+0.37

+6.52%

最高6.07	最低5.50	成交量77.51万
今开5.61	昨收5.60	日振幅10.18%
总市值1.87亿	流通市值1.10亿	总股本3,129万
成交额448.63万	换手率4.19%	流通股本1,848万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":5.965,"timestamp":1783446645498,"preClose":5.6,"halted":0,"volume":775103,"delay":0,"changeRate":0.06517857142857147,"floatShares":18481200,"shares":31289969,"eps":-3.661292,"marketStatus":"交易中","change":0.365,"latestTime":"07-07 13:50:45 EDT","open":5.61,"high":6.065,"low":5.495,"amount":4486348.095901,"amplitude":0.101786,"askPrice":5.98,"askSize":100,"bidPrice":5.95,"bidSize":1119,"shortable":0,"etf":0,"ttmEps":-3.661292,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1783454400000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":5.6,"preHourTrading":{"tag":"盘前","latestPrice":5.62,"preClose":5.6,"latestTime":"09:29 EDT","volume":3344,"amount":18810.725648,"timestamp":1783430999999,"change":0.02,"changeRate":0.003571,"amplitude":0.135714},"postHourTrading":{"tag":"盘后","latestPrice":5.4014,"preClose":5.6,"latestTime":"18:59 EDT","volume":2192,"amount":11971.8455,"timestamp":1783378775477,"change":-0.1986,"changeRate":-0.035464,"amplitude":0.035464},"volumeRatio":1.246976,"impliedVol":1.1965,"impliedVolPercentile":0.761},"requestUrl":"/m/hq/s/LENZ/wiki","defaultTab":"wiki","newsList":[{"id":"2649858622","title":"Incyte(INCY)以12.5亿美元完成收购Vega Therapeutics 拓宽血液学管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2649858622","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649858622?lang=zh_cn&edition=full","pubTime":"2026-07-06 21:19","pubTimestamp":1783343950,"startTime":"0","endTime":"0","summary":"根据双方此前达成的股票购买协议，Incyte已支付12.5亿美元的预付款，收购了Vega Therapeutics的全部发行在外股份。此外，Star Therapeutics未来还有权获得最高达7.5亿美元的商业销售里程碑付款。通过本次收购，Incyte成功将Vega的核心资产——创新单克隆抗体VGA039收入囊中。目前，该药物正在全球开展一项名为VIVID-6的单臂交叉3期临床试验，以评估其在各类血管性血友病患者中的安全性和有效性。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302236","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4139","INCY","IDNA","LENZ","BK4539","BK4550","BK4588","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183410479","title":"Lenz Therapeutics推出新型远程医疗处方方案，加速老花眼患者获取Vizz®治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1183410479","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183410479?lang=zh_cn&edition=full","pubTime":"2026-07-06 20:22","pubTimestamp":1783340531,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics宣布推出一种新型远程医疗处方方案，旨在加速老花眼患者获取Vizz®治疗。此举将简化患者的治疗流程，提高治疗的可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649197641","title":"生物技术公司Scribe Therapeutics(SCTX.US)申请美股IPO 拟筹资至多7500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649197641","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649197641?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:30","pubTimestamp":1783323045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HELX","BK4139","FRHC","LENZ","WDNA","IPOS","BK4539","BK4127","BK4007","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648509782","title":"联合治疗公司以1.4亿美元现金收购生物技术公司Thymmune Therapeutics。","url":"https://stock-news.laohu8.com/highlight/detail?id=2648509782","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648509782?lang=zh_cn&edition=full","pubTime":"2026-07-02 18:31","pubTimestamp":1782988300,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LENZ","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647426551","title":"Unicycive Therapeutics股价下跌45.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647426551","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647426551?lang=zh_cn&edition=full","pubTime":"2026-06-30 21:32","pubTimestamp":1782826373,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics股价下跌45.8%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606303788649482.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606303788649482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","UNCY","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647232807","title":"益普生将以最高17.5亿美元收购Kartos Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2647232807","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647232807?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:20","pubTimestamp":1782710416,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158361816","title":"Lenz Therapeutics与Arrotex Pharmaceuticals就Vizz™在澳大利亚和新西兰达成独家许可与商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1158361816","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158361816?lang=zh_cn&edition=full","pubTime":"2026-06-24 20:32","pubTimestamp":1782304365,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics与Arrotex Pharmaceuticals宣布，双方已就Vizz™在澳大利亚和新西兰市场达成一项独家许可与商业化合作协议。该协议的签署标志着两家公司将在上述区域共同推进Vizz™的商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645889615","title":"Definium Therapeutics(DFTX)宣布7亿美元增发公开募股定价 每股34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645889615","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645889615?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:11","pubTimestamp":1782292315,"startTime":"0","endTime":"0","summary":"金吾财讯 | 临床后期生物制药公司Definium Therapeutics 正式宣布，其已完成扩大规模的包销公开发行定价，公司将以每股34.00美元的价格公开发行20,588,236股普通股。在不扣除承销折扣、佣金及其他发行费用的情况下，Definium预计此次公开发行的募资总额将达到约7亿美元。本次发行预计将于2026年6月25日左右交割。而就在本次发行定价前不久，Definium刚于6月22日宣布，其用于治疗重度抑郁症的创新疗法“DT120口崩片”在3期临床研究中取得了积极的顶线结果。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301833","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4539","BK4139","UUP","LENZ","UDN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645685014","title":"德琪医药-B(06996)与MPM BioImpact创立的K2 Therapeutics就ATG-106达成独家授权协议 并授予其一项未披露双特异性TCE的选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2645685014","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645685014?lang=zh_cn&edition=full","pubTime":"2026-06-22 08:36","pubTimestamp":1782088596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B 发布公告，Antengene Biologics Limited与由K2 Therapeutics新成立的一家公司， 已就ATG-106订立一份独家且可再授权的授权协议。此外， K2与授权方亦已订立一份选择权协议，据此，K2已获授一项独家选择权，以取得一款未披露的临床前双特异性TCE候选药物的独家授权。MPM BioImpact是一家全球领先的生物技术投资机构，拥有逾30年创建及投资创新公司的经验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1191","BK1574","BK1583","LENZ","BK4539","06996","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642382782","title":"Viking Therapeutics任命Hubert C. Chen博士为新任首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=2642382782","media":"环球市场播报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642382782?lang=zh_cn&edition=full","pubTime":"2026-06-11 23:06","pubTimestamp":1781190360,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Viking Therapeutics周四宣布，任命Hubert C． Chen博士为首席医疗官。Chen博士将负责领导公司的临床开发、医学及监管事务，直接向公司总裁兼首席执行官Brian Lian博士汇报。在加入Viking之前，他曾担任Loyal Animal Health的首席研发官，领导了首个与美国食品药品监督管理局达成谈判的长寿疗法有效性和安全性要求制定工作。　　这一任命正值Viking推进其核心候选药物VK2735的关键时期。Viking还计划于本季度启动新型胰淀素激动剂VK3019的一期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-11/doc-inicaenm0642884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","LENZ","BK4007","BK4139","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169652203","title":"Lenz宣布与云顶新耀达成协议，后者获Vizz®(Lnz100)大中华区开发及商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1169652203","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169652203?lang=zh_cn&edition=full","pubTime":"2026-06-08 07:31","pubTimestamp":1780875098,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics公司宣布，已与Everest Medicines（云顶新耀）达成授权协议。根据协议，云顶新耀获得了在大中华区（包括中国大陆、香港、澳门及台湾）开发和商业化Vizz®（研发代号Lnz100）的独家权利。\n该交易标志着Lenz的核心产品管线进入了重要的亚太市场。Vizz®（Lnz100）是一款处于研发阶段的创新疗法，此次合作将加速该产品在广阔的大中华区的临床开发与未来市场准入。\n通过此次授权，Lenz有望获得包括首付款、里程碑付款以及基于未来销售额的特许权使用费在内的潜在收益。云顶新耀则将凭借其在本地区的开发与商业化能力，推动该产品的上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640594153","title":"Kazia Therapeutics任命资深交易专家James Levine为新任CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2640594153","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640594153?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:48","pubTimestamp":1780411680,"startTime":"0","endTime":"0","summary":"澳大利亚临床阶段肿瘤公司Kazia Therapeutics Limited宣布，任命James Levine为首席财务官，自2026年6月1日起生效。Levine拥有超过二十年的投资银行及生物技术公司高管经验，曾在高盛担任董事总经理，并领导过总计数十亿美元的生物医药交易。　　Levine近期担任Cardiff Oncology首席财务官，此前曾任Cidara Therapeutics首席财务官，主导了与Mundipharma及强生旗下Janssen Pharmaceuticals的财务架构设计。　　Kazia的核心资产paxalisib是一款口服、可入脑的PI3K/mTOR双重抑制剂，正在开发用于多种癌症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-02/doc-inhzzumh2971166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640492479","title":"Vector Science & Therapeutics授出20.6万份期权 持续推进增长战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2640492479","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640492479?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:39","pubTimestamp":1780411140,"startTime":"0","endTime":"0","summary":"Vector Science & Therapeutics Corp．周二宣布，公司董事会已批准向部分董事授予206，610份股票期权，行权价为每股1.69加元。此举正值公司近期完成多项战略布局、加速推进增长战略之际。此次期权授予尚需获得多伦多证券交易所创业板的批准。　　公司于今年4月完成在多伦多证券交易所创业板的上市，股票代码PAIN，为这一增长战略的推进提供了资本市场支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-02/doc-inhzzumk4647843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4007","VAQC","BK4561","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640954794","title":"Seaport Therapeutics将出席两大投资者会议，聚焦神经精神药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2640954794","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640954794?lang=zh_cn&edition=full","pubTime":"2026-06-01 21:09","pubTimestamp":1780319340,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics是一家专注于开发新型神经精神疾病疗法的临床阶段生物制药公司，近日宣布其管理团队将参与两场即将举行的投资者会议。　　根据公司发布的消息，Seaport将出席高盛第47届年度全球医疗保健会议，炉边谈话定于2026年6月10日上午8点举行。　　Seaport Therapeutics总部位于马萨诸塞州波士顿，于2024年成立，2026年5月1日在纳斯达克完成IPO上市，股票代码为SPTX。此次参与两大投资者会议，Seaport将向投资界分享其在神经精神药物研发领域的最新进展与战略规划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-01/doc-inhzxmef5038397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LENZ","BK4139","BK4539","SPTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639725276","title":"BMS多发性骨髓瘤III期数据亮眼 C4 Therapeutics受提振大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2639725276","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639725276?lang=zh_cn&edition=full","pubTime":"2026-05-30 03:49","pubTimestamp":1780084140,"startTime":"0","endTime":"0","summary":"百时美施贵宝日前公布了其在研药物美齐格米德的III期临床试验阳性数据。结果显示，该联合疗法将复发或难治性多发性骨髓瘤患者的疾病进展或死亡风险降低了52%。这一积极结果不仅推高了施贵宝的股价，也显著提振了同领域生物科技公司C4 Therapeutics的市场表现。　　在施贵宝宣布这一消息后，C4 Therapeutics股价应声大涨，盘中一度触及52周新高，最终收涨逾19%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-30/doc-inhzrera0552232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LENZ","III","BK4539","BK4139","BMS","BK4134","CCCC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639675738","title":"Aldeyra Therapeutics投资者迎来集体诉讼主导权申请截止日","url":"https://stock-news.laohu8.com/highlight/detail?id=2639675738","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639675738?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:54","pubTimestamp":1780066440,"startTime":"0","endTime":"0","summary":"生物制药公司Aldeyra Therapeutics近日面临证券欺诈集体诉讼，多家律所提醒投资者，申请担任首席原告的截止日期为2026年5月29日。　　此次诉讼源于美国食品药品监督管理局于2026年3月17日对该公司的干眼症候选药物reproxalap新药申请发出完全回复函，正式拒绝批准。　　诉讼指控在2023年11月3日至2026年3月16日期间，Aldeyra及其部分高管违反了联邦证券法，就reproxalap临床试验结果作出了虚假和误导性陈述，未能披露试验数据的不一致性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-29/doc-inhzqtze7774976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638684358","title":"Turn Therapeutics发表GX-03抗炎新数据，助力皮肤病精准治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2638684358","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638684358?lang=zh_cn&edition=full","pubTime":"2026-05-27 23:35","pubTimestamp":1779896100,"startTime":"0","endTime":"0","summary":"Turn Therapeutics近日宣布，一篇关于其先导候选药物GX-03在IL-36相关炎症模型中活性的同行评审研究论文，已发表于《皮肤病学治疗杂志》。该研究为GX-03治疗中重度特应性皮炎的作用机制提供了新的科学依据，标志着公司对炎症性皮肤病局部治疗研究方法的转变。就在上月，Turn Therapeutics还与Avenue Capital Group旗下基金达成了一项最高2500万美元的成长资本贷款协议，首笔700万美元已到账，将用于支持GX-03项目的推进并可能将现金跑道延续至2期数据公布之后。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-27/doc-inhzkfvc1468955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LENZ","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638896436","title":"临床阶段RNAi疗法公司Silence Therapeutics将出席Jefferies全球医疗保健年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2638896436","media":"环球市场播报","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638896436?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:37","pubTimestamp":1779892620,"startTime":"0","endTime":"0","summary":"临床阶段RNAi疗法公司Silence Therapeutics近日宣布，公司管理层将出席2026年6月3日下午4：55举行的Jefferies全球医疗保健年会，并进行分析师主导的炉边谈话。投资者可通过公司官网投资者关系页面收听现场网络直播，回放将在会议结束后提供。　　Silence Therapeutics目前最受关注的资产是divesiran，一种靶向TMPRSS6的siRNA疗法，用于治疗真性红细胞增多症。　　Silence Therapeutics总部位于伦敦，在纳斯达克以“SLN”代码交易，员工约88人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-27/doc-inhzkfvc1451718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","XLV","LENZ","VHT","BK4585","BK4588","XBI","BK4550","BK4139","BK4581","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035245","title":"Indaptus Therapeutics Q1净亏损收窄，现金储备大幅下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035245","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635035245?lang=zh_cn&edition=full","pubTime":"2026-05-15 23:46","pubTimestamp":1778859960,"startTime":"0","endTime":"0","summary":"　　Indaptus Therapeutics公布2026年第一季度财报。公司报告期内净亏损为254万美元，合每股亏损0.23美元，较上年同期的453万美元亏损和每股亏损9.11美元显著收窄。每股亏损的大幅减少主要源于2025年6月实施的1比28反向股票分割带来的股份数量增加。一般及行政费用为167万美元，同比略有下降。　　截至季末，公司现金及现金等价物仅为150万美元，较2025年末的850万美元大幅下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-15/doc-inhxyyie6357238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","LENZ","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035758","title":"Atrium Therapeutics Q1净亏损1660万美元，BMS里程碑付款支撑收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035758","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635035758?lang=zh_cn&edition=full","pubTime":"2026-05-15 23:41","pubTimestamp":1778859660,"startTime":"0","endTime":"0","summary":"　　Atrium Therapeutics公布2026年第一季度财报。公司报告期内净亏损为1663万美元，合每股亏损0.97美元。作为对比，公司在作为Avidity Biosciences子公司期间的2025年同期净亏损为745万美元，合每股亏损0.44美元。需要说明的是，由于Atrium于2026年2月27日才完成从Avidity的分拆独立上市，本期财务数据不宜直接与历史同期进行比较。　　Atrium于2月27日正式作为独立公司登陆纳斯达克。ATR 1072的IND申请预计于2026年下半年提交，ATR 1086的IND申请预计于2027年提交。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-15/doc-inhxyyie6355365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BMS","LENZ","BK4139","BK4007","BK4588","BK4505","IE0009354923.USD","RNA","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0278},{"period":"1month","weight":-0.2011},{"period":"3month","weight":-0.4233},{"period":"6month","weight":-0.6567},{"period":"1year","weight":-0.8279},{"period":"ytd","weight":-0.65}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0186},{"period":"3month","weight":0.1396},{"period":"6month","weight":0.0895},{"period":"1year","weight":0.2014},{"period":"ytd","weight":0.1017}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LENZ Therapeutics, Inc.最初于2017年6月1日在加拿大安大略省注册成立，随后于2019年10月在特拉华州重新注册成立。该公司是一家商业制药公司，专注于开发和商业化改善视力的疗法，其主导产品VIZZ被批准用于治疗老花眼。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":-0.009929},{"month":7,"riseRate":0.5,"avgChangeRate":0.041886},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}